MYX.AX - Mayne Pharma Group Limited

ASX - ASX Delayed price. Currency in AUD
+0.00 (+0.23%)
At close: 3:59PM AEST
Stock chart is not supported by your current browser
Previous close0.87
Bid0.87 x 0
Ask0.88 x 0
Day's range0.85 - 0.88
52-week range0.59 - 1.16
Avg. volume5,246,302
Market cap1.356B
PE ratio (TTM)N/A
EPS (TTM)-0.11
Earnings date24 Aug. 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend date2011-03-03
1y target est0.75
  • Best ASX Growth Companies
    Simply Wall St.12 days ago

    Best ASX Growth Companies

    Companies such as Propel Funeral Partners and Jumbo Interactive have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio shouldRead More...

  • Mayne Pharma expects "soft" H1 to improve
    AAP7 months ago

    Mayne Pharma expects "soft" H1 to improve

    Drugs manufacturer Mayne Pharma is still feeling the impact of tough competition and lower prices in the generic drugs market in the US, but expects the release of new drugs and restructuring initiatives will boost the company's financial performance. Chief executive Scott Richards says the company's first half is expected to be "soft" but that a range of initiatives is already yielding benefits. Shares in Mayne Pharma dropped 1.5 cents, or 2.4 per cent, to 61 cents.

  • AAP7 months ago

    Mayne Pharma warns of 'soft' first half

    Mayne Pharma's revenue for the first four months of the financial year dropped 12 per cent due to price deflation in the US generic marketplace. Chief executive Scott Richards says group revenue to the ...